NVCR NovoCure Ltd
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1645113 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.9%
TTM net income YoY31.5%
TTM EPS YoY34.2%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin-17.2%
Net margin-16.8%
FCF margin-3.4%
EBITDA margin-14.8%
Returns
ROE-35.2%
ROA-11.1%
ROIC (approx.)-77.8%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets57.7%
Debt / equity0.00x
Current ratio2.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.01x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $655.35M | $605.22M |
| Cost of revenue | $166.88M | $137.18M |
| Gross profit | $488.47M | $468.04M |
| R&D expense | $224.54M | $209.65M |
| SG&A expense | $177.67M | $189.83M |
| Operating income | -$153.80M | -$170.50M |
| Interest expense | $22.22M | $11.66M |
| Pretax income | -$136.25M | -$131.16M |
| Income tax | -$23,000 | $37.47M |
| Net income | -$136.23M | -$168.63M |
| EBITDA | -$139.15M | -$159.26M |
| EPS (basic) | -1.22 | -1.56 |
| EPS (diluted) | -1.22 | -1.56 |
| Weighted avg. shares (diluted) | 111.47M | 107.83M |
| Balance sheet | ||
| Cash & equivalents | $93.55M | $166.09M |
| Receivables | $89.44M | $74.23M |
| Inventory | $41.11M | $35.09M |
| Current assets | $646.73M | $1.11B |
| PP&E, net | $77.61M | $77.66M |
| Total assets | $804.33M | $1.24B |
| Current liabilities | $223.23M | $756.39M |
| Short-term debt | $0 | — |
| Long-term debt | $195.05M | $97.30M |
| Total debt | $195.05M | $97.30M |
| Total liabilities | $463.86M | $880.61M |
| Shareholders' equity | $340.47M | $360.18M |
| Net debt | $101.50M | -$68.79M |
| Shares outstanding | 112.49M | 108.52M |
| Cash flow statement | ||
| Operating cash flow | -$49.03M | -$26.37M |
| Capital expenditure | $26.65M | $42.85M |
| Free cash flow | -$75.68M | -$69.22M |
| Investing cash flow | $437.28M | -$140.24M |
| Financing cash flow | -$451.34M | $90.31M |
| Depreciation & amortization | $14.65M | $11.23M |
| Stock-based compensation | $104.83M | $160.03M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.